Table 4. Multivariable analyses of 10-year distant disease-free survival in all premenopausal patients with node-negative breast cancer where complete data on all proliferations factors was available (n=162, left), and in the ER-positive patients only (n=114, right).

		All patients (n=162, 35 events)			ER-positive patients (n=114, 23 events)
Factor		Hazard Ratio	95% Confidence Interval	p-value	Hazard Ratio	95% Confidence Interval	p-value
MAI	high vs low	2.7	1.1-6.7	0.035	5.9	2.4-15	<0.001
PPH3	high vs low	1.4	0.66-3.1	0.37	1.8	0.70-4.8	0.22
Cyclin B1	high vs low	1.5	0.62-3.7	0.36	1.8	0.59-5.4	0.31
Cyclin A	high vs low	2.7	1.2-6.0	0.019	3.1	1.2-8.0	0.016
Ki67	high vs low	1.8	0.81-4.1	0.15	3.6	1.4-8.9	0.007
MAI and/or PPH3 high	high vs low	2.0	0.89-4.7	0.093	3.3	1.4-7.9	0.008
MAI and/or cyclin B1 high	high vs low	2.6	1.1-6.2	0.027	4.0	1.6-10	0.003
MAI and/or cyclin A high	high vs low	3.8	1.6-8.7	0.002	4.9	2.0-12	<0.001
MAI and/or Ki67 high	high vs low	2.9	1.3-6.8	0.013	4.7	1.9-11	0.001

All models are adjusted for age, ER-status (not in the ER-positive patients), HER2-status, and adjuvant medical treatment.